About the Authors
- Costanza Bogani
-
Contributed equally to this work with: Costanza Bogani, Niccolò Bartalucci
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Niccolò Bartalucci
-
Contributed equally to this work with: Costanza Bogani, Niccolò Bartalucci
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Serena Martinelli
-
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Lorenzo Tozzi
-
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Paola Guglielmelli
-
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Alberto Bosi
-
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
- Alessandro M. Vannucchi
-
* E-mail: amvannucchi@unifi.it
Affiliation Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy
Competing Interests
A.M. Vannucchi, participated in advisory board meeting (Novartis, Italfarmaco). The JAK1/JAK2 kinase ATP-competitive inhibitors AZD1480 [44] and INC424 (ruxolitinib) were provided by D. Huszar (AstraZeneca, Waltham, MA, USA) and T. Radimeski (Novartis, Basel, CH), respectively. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CB NB PG AMV. Performed the experiments: CB NB SM LT PG. Analyzed the data: CB NB LT PG AB AMV. Wrote the paper: CB NB LT PG AMV.